During a press conference to announce a drug price deal for GLP-1s, President Donald Trump asked for more details about the ...

Darzalex Faspro’s approval for smoldering multiple myeloma could allow for earlier intervention and reduce the risk of ...

Following restricted vaccine approvals and changes to CDC immunization schedules, Merck, Pfizer, GSK and Sanofi are all ...

The FDA previously placed two clinical studies on hold, including the Phase III trial in which the liver toxicity occurred.

James O’Mara is president and chief executive officer at, Neurogastrx, Inc.

The Phase III results impressed Guggenheim Partners analysts both in terms of efficacy and safety. If approved, atacicept would become the first APRIL/BAFF inhibitor for IgAN to make it to the market.

The nausea and other gastrointestinal side effects of weight loss drugs like Novo Nordisk’s Wegovy or Eli Lilly’s Zepbound will limit how much these drugs can help patients and stunt the overall ...